Chris Chapman

MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) announced on Thursday the results from a preclinical study of its investigational cannabinoid Supera-CBD, a novel, synthetic, non-toxic cannabidiol (CBD) analog. In the study, Supera-CBD targeted and quickly reduced inflammatory pain within 60 minutes,...